Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era

George, MP and Kannass, M and Huang, L and Sciurba, FC and Morris, A (2009) Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS ONE, 4 (7).

Published Version
Available under License : See the attached license file.

Download (104kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Prevalence and risk factors for respiratory symptoms and airway obstruction in HIV-infected subjects in the era of highly active antiretroviral therapy (HAART) are unknown. We evaluated respiratory symptoms and measured airway obstruction to identify the impact of HAART and other risk factors on respiratory symptoms and pulmonary function. Methodology/Principal Findings: Two hundred thirty-four HIV-infected adults without acute respiratory symptoms were recruited from an HIV clinic. All subjects were interviewed and performed spirometry. Multivariate linear and logistic regressions were performed to determine predictors of respiratory symptoms, forced expiratory volume in one second (FEV1) percent predicted, and FEV1/forced vital capacity (FEV1 / FVC). Thirty-one percent of subjects reported at least one respiratory symptom. Smoking status (current or former versus never) (odds ratio [OR] = 2.7, 95% confidence interval [CI] = 1.41-5.22, p = 0.003), higher log plasma HIV viral levels (OR = 1.12, 95%CI = 1.02-1.24, p = 0.02), and lower FEV1/FVC (OR = 1.06 for every 0.01 decrease in FEV1/FVC, 95%CI = 1.02-1.14, p = 0.001) were independent predictors of respiratory symptoms. Age (p = 0.04), pack-year smoking history (p<0.001), previous bacterial pneumonia (p = 0.007), and HAART use (p = 0.04) were independent predictors of decreased FEV1/FVC. Conclusions/Significance: Respiratory symptoms remain common in HIV-infected subjects, especially in those with a smoking history. Subjects who were older, had a greater pack-year history of smoking, or previous bacterial pneumonia had lower FEV1/FVC ratios. Interestingly, use of HAART was independently associated with a decreased FEV1/FVC, possibly secondary to an immune response to subclinical infections, increased autoimmunity, or other factors associated with HAART use. © 2009 George et al.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
George, MP
Kannass, M
Huang, L
Sciurba, FCfcs@pitt.eduFCS
Morris, A
ContributionContributors NameEmailPitt UsernameORCID
Date: 21 July 2009
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 4
Number: 7
DOI or Unique Handle: 10.1371/journal.pone.0006328
Refereed: Yes
MeSH Headings: Adult; Aged; Antiretroviral Therapy, Highly Active; Female; HIV Infections--drug therapy; HIV Infections--physiopathology; Humans; Male; Middle Aged; Respiratory Function Tests; Risk Factors
PubMed Central ID: PMC2709444
PubMed ID: 19621086
Date Deposited: 03 Aug 2012 15:09
Last Modified: 22 Jun 2021 13:56


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item